澳大利亚子宫肌瘤发病率和患病率的首次估计:2000-2022年数据链接队列研究
该研究基于澳大利亚女性健康纵向研究,纳入8066名1973-1978年出生的女性,结合自我报告调查与行政健康数据链接,随访22年。估计7.3%的女性在45-49岁前被诊断为子宫肌瘤,40-44岁年龄别发病率最高(5.0例/1000人年)。子宫肌瘤女性更易报告月经量多或痛经、低铁水平、子宫内膜异位症及自评健康差。
要点
- 估计7.3%的澳大利亚女性在45-49岁前被诊断为子宫肌瘤(95%CI 6.9-7.6)。
- 40-44岁女性年龄别发病率最高,为5.0例/1000人年(95%CI 4.3-5.7)。
- 子宫肌瘤女性更易出现月经量多或痛经、低铁水平、子宫内膜异位症和自评健康差。
核心结论
- 这是澳大利亚育龄女性子宫肌瘤患病率和发病率的首次基于人群的估计。
- 建立这些首次估计将有助于为澳大利亚背景下的卫生政策和卫生保健提供信息。
研究设计与样本
- 观察性前瞻性队列研究,使用自我报告调查和链接行政数据(2000-2022年)。
- 纳入澳大利亚女性健康纵向研究中8066名1973-1978年出生的女性。
- 结合自我报告调查与链接行政健康数据(医院、急诊科、医疗保险福利计划、药品福利计划)识别2000-2022年间报告子宫肌瘤诊断的女性。
主要发现
- 8066名澳大利亚女性随访22年,估计7.3%的女性(95%CI 6.9-7.6)在45-49岁前被诊断为子宫肌瘤。
- 发病率随年龄增加,40-44岁女性最高(5.0例/1000人年,95%CI 4.3-5.7例/1000人年)。
- 子宫肌瘤女性更可能经历月经量多或痛经。
- 子宫肌瘤女性也更可能报告低铁水平、子宫内膜异位症和自评健康差,以及每年两次或以上全科医生就诊。
局限性
- 估计基于医生诊断或治疗的自我报告和/或与治疗及操作行政记录链接的数据。
- 这主要捕获有症状的子宫肌瘤女性,但有可能对无症状女性错误分类,并低估总体患病率和发病率。
- 此外,关于子宫肌瘤的问题仅在女性37-42岁至43-48岁时的调查中询问,因此年轻年龄的病例可能被低估(尤其是症状较轻的女性),因为这些仅通过数据链接确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the estimated prevalence and incidence of uterine fibroids diagnosed in Australian women of reproductive age? SUMMARY ANSWER: An estimated 7.3% of Australian women had a diagnosis of uterine fibroids by the age of 45-49 years, with age-specific incidence highest in women aged 40-44 years (5.0 cases per 1000 person-years). WHAT IS KNOWN ALREADY: Uterine fibroids are associated with a high symptom burden and may affect overall health and quality of life. Studies in different countries show a wide variation in both the prevalence (4.5-68%) and incidence (2.2-37.5 per 1000 person-years) of uterine fibroids, which may be partly explained by the type of investigation, method of case ascertainment, or the age range of the study population, necessitating the reporting of country-specific estimates. STUDY DESIGN, SIZE, DURATION: This observational prospective cohort study using self-report survey and linked administrative data (2000-2022) included 8066 women, born between 1973 and 1978, in the Australian Longitudinal Study on Women's Health. PARTICIPANTS/MATERIALS, SETTING, METHODS: A combination of self-report survey and linked administrative health data (hospital, emergency department, the Medicare Benefits Schedule, and the Pharmaceutical Benefits Scheme) were used to identify women with a report of a diagnosis of uterine fibroids between 2000 and 2022. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 8066 Australian women followed for 22 years, an estimated 7.3% of women (95% CI 6.9, 7.6) had a diagnosis of uterine fibroids by the age of 45-49 years. The incidence increased with age and was highest in women aged 40-44 years (5.0 cases per 1000 person-years, 95% CI 4.3, 5.7 cases per 1000 person-years). Women with uterine fibroids were more likely to experience heavy or painful periods. They were also more likely to report low iron levels, endometriosis, and poor self-rated health and to have two or more annual visits to their general practitioner. LIMITATIONS, REASONS FOR CAUTION: Our estimates are based on self-report of doctor diagnosis or treatment for fibroids and/or data linked to treatment and procedure administrative records. This predominantly captures women with symptomatic fibroids, but has the potential for misclassification of asymptomatic women and an underestimate of overall prevalence and incidence. In addition, questions on fibroids were only asked in surveys when women were 37-42 years of age to 43-48 years of age, so cases at younger ages may have been underestimated (particularly in women with less severe symptoms) as these were only ascertained through data linkage. WIDER IMPLICATIONS OF THE FINDINGS: These are the first population-based estimates of the prevalence and incidence of uterine fibroids in women of reproductive age in Australia. Establishing these first estimates will help inform health policy and health care provision in the Australian context. STUDY FUNDING/COMPETING INTEREST(S): The ALSWH is funded by the Australian Government Department of Health and Aged Care. L.FW. was supported by an Australian National Health and Medical Research Council (NHMRC) Centres for Research Excellence grant (APP1153420) and G.D.M. was supported by an NHMRC Leadership Fellowship (APP2009577). The funding bodies played no role in the design, the collection, analysis or interpretation of data, the writing of the manuscript, or the decision to submit the manuscript for publication. There are no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Wilson LF, Moss KM, Doust J, et al. First Australian estimates of incidence and prevalence of uterine fibroids: a data linkage cohort study 2000-2022. Hum Reprod. 2024. PMID: 39013145. doi:10.1093/humrep/deae162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。